Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CD70 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences)
- Development stage
- Phase 1
- Lead developer
- Academy of Military Medical Sciences
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
BCMA-CD70 CAR-T cells is a dual-targeted chimeric antigen receptor (CAR) T-cell therapy being developed by the Affiliated Hospital to the Academy of Military Medical Sciences. It is designed to simultaneously target B-cell maturation antigen (BCMA) and CD70, two proteins frequently overexpressed on the surface of malignant plasma cells. By targeting two antigens, the therapy aims to overcome antigen escape and improve the depth and durability of response in patients with high-risk plasma cell neoplasms, such as multiple myeloma. The treatment involves the infusion of autologous T cells genetically engineered to express CARs against both targets, typically following a lymphodepleting chemotherapy regimen of fludarabine and cyclophosphamide.
- Other names
- BCMA-CD70 dual-target CAR-T therapyBCMA-CD-70 dual-target CAR-T therapyBCMA-CD 70 dual-target CAR-T therapyCAR BCMA-CD70-T cells
02
Targets
CD70 (Cluster of Differentiation 70)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA-CD70 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CD70 CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences).